Jack Khattar, president & CEO of Supernus, said the company remain[s] committed to bringing SPN-830 to the market and will work with the FDA to address the issues identified in the CRL and resubmit the NDA
Most patients notice visible results within three to five sessions
This out-of-pocket expense affects treatment decisions for many Canadians, particularly those comparing long-term costs between different approaches
Citations [1] Mikus D, Sikiric P, Seiwerth S, Petricevic A, Aralica G, Druzijancic N, Rucman R, Petek M, Pigac B, Perovic D, Kolombo M, Kokic N, Mikus S, Duplancic B, Fattorini I, Turkovic B, Rotkvic I, Mise S, Prkacin I, Konjevoda P, Stambuk N, Anic T
Fibroblast growth factor signaling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer
References D'Souza SW, Glazier JD